ATE416164T1 - Pharmazeutische zusammenstellungen zur prävention und behandlung von zns-erkrankungen - Google Patents
Pharmazeutische zusammenstellungen zur prävention und behandlung von zns-erkrankungenInfo
- Publication number
- ATE416164T1 ATE416164T1 AT97921232T AT97921232T ATE416164T1 AT E416164 T1 ATE416164 T1 AT E416164T1 AT 97921232 T AT97921232 T AT 97921232T AT 97921232 T AT97921232 T AT 97921232T AT E416164 T1 ATE416164 T1 AT E416164T1
- Authority
- AT
- Austria
- Prior art keywords
- prevention
- treatment
- pharmaceutical compositions
- aryl substituted
- cns diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63176196A | 1996-04-23 | 1996-04-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE416164T1 true ATE416164T1 (de) | 2008-12-15 |
Family
ID=24532629
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT97921232T ATE416164T1 (de) | 1996-04-23 | 1997-04-16 | Pharmazeutische zusammenstellungen zur prävention und behandlung von zns-erkrankungen |
Country Status (12)
Country | Link |
---|---|
US (2) | US6603011B1 (de) |
EP (2) | EP1997806A1 (de) |
JP (2) | JP4357001B2 (de) |
AT (1) | ATE416164T1 (de) |
AU (1) | AU727976B2 (de) |
BR (1) | BR9708815B1 (de) |
CA (1) | CA2252515C (de) |
DE (1) | DE69739142D1 (de) |
DK (1) | DK0900200T5 (de) |
ES (1) | ES2318856T4 (de) |
PT (1) | PT900200E (de) |
WO (1) | WO1997040011A1 (de) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6979695B2 (en) * | 1996-04-23 | 2005-12-27 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
US6166048A (en) * | 1999-04-20 | 2000-12-26 | Targacept, Inc. | Pharmaceutical compositions for inhibition of cytokine production and secretion |
US20020052497A1 (en) | 2000-03-09 | 2002-05-02 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
KR20010052171A (ko) | 1998-04-02 | 2001-06-25 | 알. 제이. 레이놀즈 터베코 컴퍼니 | 의약 조성물 및 그 사용방법 |
US7790757B2 (en) | 1998-06-16 | 2010-09-07 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
US6232316B1 (en) | 1998-06-16 | 2001-05-15 | Targacept, Inc. | Methods for treatment of CNS disorders |
US20050131034A1 (en) * | 1998-06-16 | 2005-06-16 | Caldwell William S. | Compounds capable of activating cholinergic receptors |
ES2228054T3 (es) * | 1998-06-16 | 2005-04-01 | Targacept, Inc. | Aminas olefinicas sustituidas con arilo y su uso como agonistas de receptores colinergicos. |
US6455734B1 (en) | 2000-08-09 | 2002-09-24 | Magnesium Diagnostics, Inc. | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states |
AU2005201609B2 (en) * | 1999-04-20 | 2007-10-18 | Targacept, Inc | Pharmaceutical compositions for inhibition of cytokine production and secretion |
US20010031771A1 (en) | 1999-05-24 | 2001-10-18 | Gary Maurice Dull | Pharmaceutical compositions and methods for use |
AU5326100A (en) * | 1999-06-07 | 2000-12-28 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
MXPA02001095A (es) * | 1999-07-30 | 2002-08-20 | Vertex Pharma | Derivados de amina ciclicos y aciclicos. |
WO2001082978A2 (en) * | 2000-05-01 | 2001-11-08 | Targacept, Inc. | Imaging of nicotinic acetylcholine receptor subtypes |
FR2838436A1 (fr) * | 2002-04-16 | 2003-10-17 | Rhodia Chimie Sa | Composes amines porteurs d'au moins un allyle et d'un difluoromethyle et procede utile a leur synthese |
EP1494994A2 (de) * | 2002-04-16 | 2005-01-12 | Rhodia Chimie | Aminierte verbindungen, die wenigstens ein allyl und ein difluormethyl tragen, und bei deren synthese angewendete verfahren |
FR2847578A1 (fr) * | 2002-11-21 | 2004-05-28 | Rhodia Chimie Sa | Composes amines porteurs d'au moins un allyle et d'un difluoromethyle et procede utile a leur synthese |
US7731740B2 (en) * | 2004-04-02 | 2010-06-08 | Arterial Remodelling Technologies, Inc. | Polymer-based stent assembly |
US7459469B2 (en) | 2004-11-10 | 2008-12-02 | Targacept, Inc. | Hydroxybenzoate salts of metanicotine compounds |
UA88792C2 (ru) | 2004-11-10 | 2009-11-25 | Таргасепт, Інк. | Гидроксибензоатные соли метаникотиновых соединений |
CN101528698A (zh) | 2006-05-09 | 2009-09-09 | 阿斯利康公司 | (2s)-(4e)-n-甲基-5-[3-(5-异丙氧基吡啶)基]-4-戊烯-2-胺的盐形式 |
TWI389889B (zh) * | 2006-05-09 | 2013-03-21 | Targacept Inc | (2s)-(4e)-n-甲基-5-〔3-(5-異丙氧基吡啶)基〕-4-戊烯-2-胺之新穎多晶型 |
AR062860A1 (es) * | 2006-09-15 | 2008-12-10 | Astrazeneca Ab | Combinaciones terapeuticas 482 |
US20100028447A1 (en) * | 2007-01-22 | 2010-02-04 | Targacept, Inc. | Intranasal, Buccal, And Sublingual Administration Of Metanicotine Analogs |
EP2647373A1 (de) | 2008-05-12 | 2013-10-09 | Targacept, Inc. | Verfahren zur Prävention der Entwicklung von Retinopathie durch orale Verabreichung von Exo-S-Mecamylamine |
WO2010080757A2 (en) | 2009-01-07 | 2010-07-15 | Astrazeneca Ab | Combinations with an alpha-4beta-2 nicotinic agonist |
WO2011146009A1 (en) | 2010-05-20 | 2011-11-24 | Targacept Inc. | New process for the preparation of aryl substituted olefinic amines |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4965074A (en) | 1985-03-05 | 1990-10-23 | Ciba-Geigy Corporation | Method of treating memory impairment |
US4684654A (en) * | 1985-08-14 | 1987-08-04 | American Cyanamid Company | 3-heteroalkyl-2,4-quinzaolinediones |
US4788206A (en) * | 1987-07-10 | 1988-11-29 | Hoffmann-La Roche Inc. | Pentadieneamides |
US4927838A (en) * | 1987-07-10 | 1990-05-22 | Hoffman-La Roche Inc. | Pyridine compounds which are useful in treating a disease state characterized by an excess of platelet activating factors |
US4786646A (en) * | 1987-07-10 | 1988-11-22 | Hoffmann-La Roche Inc. | Cyclopropylpropenamides |
US4922901A (en) | 1988-09-08 | 1990-05-08 | R. J. Reynolds Tobacco Company | Drug delivery articles utilizing electrical energy |
US5210076A (en) | 1988-09-13 | 1993-05-11 | Berliner David L | Methods of treating Parkinson's disease using melanin |
US5356906A (en) | 1989-10-27 | 1994-10-18 | The Du Pont Merck Pharmaceutical Company | (N-phthalimidoalkyl) piperidines useful as treatments for psychosis |
DE4102289A1 (de) | 1991-01-26 | 1992-07-30 | Bayer Ag | Verfahren zur herstellung von (hetero)arylalk(en/in)-ylaminen und neue (hetero)arylkinylamine |
DK0588917T3 (da) | 1991-05-29 | 2001-02-12 | Abbott Lab | Isoxazol- og isothiazolforbindelser, som forstærker kognitiv funktion |
US5212188A (en) | 1992-03-02 | 1993-05-18 | R. J. Reynolds Tabacco Company | Method for treatment of neurodegenerative diseases |
US5242935A (en) | 1992-03-06 | 1993-09-07 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
US5227391A (en) | 1992-04-10 | 1993-07-13 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
US5723477A (en) | 1994-11-10 | 1998-03-03 | Sibia Neurosciences, Inc. | Modulators of acetylcholine receptors |
US5616707A (en) | 1995-01-06 | 1997-04-01 | Crooks; Peter A. | Compounds which are useful for prevention and treatment of central nervous system disorders |
AU4610896A (en) * | 1995-01-06 | 1996-07-24 | R.J. Reynolds Tobacco Company | Pharmaceutical compositions for prevention and treatment of central nervous system disorders |
US5597919A (en) | 1995-01-06 | 1997-01-28 | Dull; Gary M. | Pyrimidinyl or Pyridinyl alkenyl amine compounds |
US5616716A (en) * | 1996-01-06 | 1997-04-01 | Dull; Gary M. | (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds |
-
1997
- 1997-04-16 EP EP08014695A patent/EP1997806A1/de not_active Withdrawn
- 1997-04-16 AT AT97921232T patent/ATE416164T1/de active
- 1997-04-16 EP EP97921232A patent/EP0900200B9/de not_active Expired - Lifetime
- 1997-04-16 WO PCT/US1997/006398 patent/WO1997040011A1/en active IP Right Grant
- 1997-04-16 ES ES97921232T patent/ES2318856T4/es not_active Expired - Lifetime
- 1997-04-16 PT PT97921232T patent/PT900200E/pt unknown
- 1997-04-16 BR BRPI9708815-3A patent/BR9708815B1/pt not_active IP Right Cessation
- 1997-04-16 DK DK97921232T patent/DK0900200T5/da active
- 1997-04-16 AU AU27332/97A patent/AU727976B2/en not_active Ceased
- 1997-04-16 DE DE69739142T patent/DE69739142D1/de not_active Expired - Lifetime
- 1997-04-16 CA CA002252515A patent/CA2252515C/en not_active Expired - Fee Related
- 1997-04-16 JP JP53818097A patent/JP4357001B2/ja not_active Expired - Fee Related
-
2000
- 2000-08-21 US US09/642,351 patent/US6603011B1/en not_active Expired - Fee Related
-
2001
- 2001-10-09 US US09/973,419 patent/US6555684B2/en not_active Expired - Fee Related
-
2008
- 2008-03-11 JP JP2008060649A patent/JP2008247903A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2252515A1 (en) | 1997-10-30 |
EP1997806A1 (de) | 2008-12-03 |
WO1997040011A1 (en) | 1997-10-30 |
BR9708815B1 (pt) | 2009-01-13 |
BR9708815A (pt) | 2000-01-04 |
JP4357001B2 (ja) | 2009-11-04 |
PT900200E (pt) | 2009-02-26 |
US6603011B1 (en) | 2003-08-05 |
EP0900200B9 (de) | 2009-10-21 |
EP0900200A1 (de) | 1999-03-10 |
DK0900200T5 (da) | 2010-01-11 |
AU2733297A (en) | 1997-11-12 |
AU727976B2 (en) | 2001-01-04 |
JP2008247903A (ja) | 2008-10-16 |
ES2318856T3 (es) | 2009-05-01 |
EP0900200B1 (de) | 2008-12-03 |
DE69739142D1 (de) | 2009-01-15 |
ES2318856T4 (es) | 2010-03-03 |
US6555684B2 (en) | 2003-04-29 |
DK0900200T3 (da) | 2009-03-30 |
CA2252515C (en) | 2006-11-07 |
US20020032206A1 (en) | 2002-03-14 |
JP2000509041A (ja) | 2000-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE416164T1 (de) | Pharmazeutische zusammenstellungen zur prävention und behandlung von zns-erkrankungen | |
ATE334668T1 (de) | Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen | |
ATE142877T1 (de) | Melatoninderivate zur behandlung von schlafstörungen und zur pre-anästhesie | |
ATE71629T1 (de) | Methylenphosphonalkylphosphinate, pharmazeutische zubereitungen und verfahren zur behandlung abnormalen kalzium- und phosphat-stoffwechsels. | |
IL192287A0 (en) | Pharmaceutical compositions and methods for use | |
ATE334120T1 (de) | Pharmazeutische zusammensetzungen zur vorbeugung und behandlung von störungen des zentralnervensystems | |
ATE66149T1 (de) | Pharmazeutische dosierungseinheit zur vorbeugung bzw. behandlung von klimakterischen beschwerden. | |
DE69837322D1 (de) | Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln | |
NO864443D0 (no) | Fremgangsmaate for fremstilling av terapeutisk aktive n-substituerte 3-piperidin- eller 3-pyridin-karboksylsyrederivater. | |
ATE125704T1 (de) | Behandlung neurodegenerativer erkrankungen. | |
ATE217191T1 (de) | Verwendung von phanquinon zur behandlung von alzheimer's krankheit | |
DE59209728D1 (de) | VERWENDUNG VON ANTAGONISTEN ODER PARTIELLEN AGONISTEN AM 5-HT 1a-REZEPTOR ZUR BEHANDLUNG UND PRÄVENTION VON KOGNITIVEN STÖRUNGEN | |
ATE239470T1 (de) | Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen | |
ATE222491T1 (de) | Melatonin-derivate zur verwendung in der behandlung von schlafstörungen | |
DE69926794D1 (de) | Ponazuril zur behandlung von durch coccidia neurologischen und "abortigenic" verursachten erkrankungen | |
DK1255734T3 (da) | Hidtil ukendte isatin-derivater | |
DE60121978D1 (de) | 7-CHLOR-4-HYDROXY-2-(2-PYRIDYLETHYL)-1,2,5,10-TETRAHYDROPYRIDAZINOi4,5-BöCHINOLIN-1,10-DIONE UND IHRE VERWENDUNG ZUR BEHANDLUNG VON SCHMERZEN | |
ATE242766T1 (de) | Neue derivate von benzoylalkyl-1,2,3,6- tetrahydropyridinen | |
DE69928814D1 (de) | Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten | |
ATE314339T1 (de) | Polyhydroxyphenolderivate und mittel zur vorbeugung und therapie von knochen- und knorpelkrankheiten die diese enthalten | |
ATE211914T1 (de) | Wismuth enthaltende zusammensetzungen zur verhütung und behandlung gastrointestinaler beschwerden |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 0900200 Country of ref document: EP |
|
EETR | Correction of the translation as to par. 6/3 patv-eg |